STONY BROOK, NY / ACCESSWIRE / March 14, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in PCR-based DNA technologies, will showcase its Linea IVT and Linea DNA platforms at the 24th Annual World Vaccine Congress, which will be held April 1 - 4, 2024. Applied DNA sales team members will be available during the Congress for one-on-one meetings.
Location:
Walter E. Washington Convention Center, Washington, D.C.
Tickets:
Visit the conference website.
Schedule a meeting: link
About the Linea DNA and Linea IVT Platforms
The Linea DNA platform is a completely cell-free DNA production platform founded on Applied DNA's long-standing expertise in the large-scale enzymatic production of DNA. Capable of producing DNA in quantities ranging from milligrams to grams, the Linea DNA platform can produce high-fidelity DNA constructs ranging from 100bp to 20kb in size. The DNA produced via the Linea DNA platform is free of the adventitious DNA sequences found in other sources of DNA, is rapidly scalable, and provides for simple chemical modification of DNA constructs.
The Linea IVT platform combines DNA IVT templates manufacturing via the Linea DNA platform with a proprietary Linea RNAP to enable mRNA and sa-mRNA manufacturers to produce what Applied DNA believes to be better mRNA faster, with advantages over conventional mRNA production, including: 1) the elimination of plasmid DNA as a starting material; 2) the prevention or reduction of dsRNA contamination; and 3) simplified mRNA production workflows.
About Applied DNA Sciences
Applied DNA Sciences is a biotechnology company developing technologies to produce and detect deoxyribonucleic acid ("DNA"). Using the polymerase chain reaction ("PCR") to enable both the production and detection of DNA, we operate in three primary business markets: (i) the enzymatic manufacture of synthetic DNA for use in the production of nucleic acid-based therapeutics and, through our recent acquisition of Spindle Biotech, Inc. ("Spindle"), the development and sale of a proprietary RNA polymerase ("RNAP") for use in the production of mRNA therapeutics; (ii) the detection of DNA and RNA in molecular diagnostics and genetic testing services; and (iii) the manufacture and detection of DNA for industrial supply chain security services.
Visit adnas.com for more information. Follow us on X and LinkedIn. Join our mailing list.
Forward-Looking Statements
The statements made by Applied DNA in this press release may be "forward-looking" in nature within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe Applied DNA's future plans, projections, strategies, and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. Actual results could differ materially from those projected due to its history of net losses, limited financial resources, unknown future demand for its biotherapeutics products and services, the inherent risk and unknown outcome of research and development projects, the unknown amount of revenues and profits that will result from the Linea DNA and/or Linea IVT platforms, the fact that there has never been a commercial drug product utilizing PCR-produced DNA technology and/or the Linea IVT or Linea DNA platforms approved for human therapeutic use, our need to raise substantial additional funds, and various other factors detailed from time to time in Applied DNA's SEC reports and filings, including its Annual Report on Form 10-K, as amended, filed on December 7, 2023, and Quarterly Report on Form 10-Q filed on February 8, 2024, and other reports it files with the SEC, which are available at www.sec.gov. Applied DNA undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date hereof or to reflect the occurrence of unanticipated events unless otherwise required by law.
Contacts:
Applied DNA Sciences Investor Relations contact: Sanjay M. Hurry, 917-733-5573, sanjay.hurry@adnas.com Web: Twitter: @APDN
Linea DNAプラットフォームは、DNAの大規模な酵素生産におけるApplied DNAの長年の専門知識に基づいて構築された、完全に無細胞なDNA生産プラットフォームです。ミリグラムからグラムまでの量のDNAを生産できるLinea DNAプラットフォームは、100bpから20kbのサイズまでの高忠実度のDNA構築物を生産できます。Linea DNAプラットフォームを介して生成されたDNAには、他のDNAソースに見られる不定型のDNA配列が含まれておらず、迅速に拡張でき、DNA構造の化学修飾も簡単です。
Linea IVTプラットフォームは、Linea DNAプラットフォームを介したDNA IVTテンプレート製造と独自のLinea RNAPを組み合わせて、mRNAおよびsa-mRNAメーカーが、1）出発物質としてのプラスミドDNAの除去、2）dsRNA汚染の防止または削減、3）mRNA生成の簡略化など、従来のmRNA製造よりも優れたmRNA製造よりも優れたmRNA製造に勝る利点とともに、mRNAおよびsa-mRNAメーカーがApplied DNAがより良いmRNAであると考えるものをより早く生産できるようにします。ワークフロー。
応用DNA科学について
Applied DNA Sciencesは、デオキシリボ核酸（「DNA」）を生成および検出する技術を開発しているバイオテクノロジー企業です。ポリメラーゼ連鎖反応（「PCR」）を使用してDNAの生成と検出の両方を可能にすることで、私たちは3つの主要なビジネス市場で事業を展開しています。（i）核酸ベースの治療薬の製造に使用する合成DNAの酵素製造、そして最近Spindle Biotech、Inc.（「Spindle」）を買収したことで、独自のRNAポリメラーゼ（「RNAP」）の開発と販売です。）mRNA治療薬の製造用、（ii）分子診断および遺伝子検査サービスにおけるDNAおよびRNAの検出、および（iii）製造および検出産業サプライチェーンセキュリティサービスのためのDNA。
